Therefore, mitochondria and OXPHOS represent metabolic vulnerabilities to exploit for the design of new and more effective therapeutic strategies targeting both PGC1-α-positive melanomas and BRAF mutant melanomas (31). This evidence concerns the gene BRAF and melanoma.